Phase 2 Autism Spectrum Disorder Trial, Recruiting NCT07091279 Sponsor: Jeremy Veenstra-vanderweele Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 2 Autism Spectrum Disorder Trial, Recruiting

NCT07091279
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 12 and 40 years old.
  • You have been diagnosed with autism spectrum disorder (ASD) based on a doctor's best clinical judgment.
  • You have had serious challenging behaviors — such as aggression, self-harm, or severely disruptive or destructive behavior — that cause safety concerns or significantly affect quality of life, happening at least once a week over the past 2 months.
  • You have had a formal autism assessment (called the ADOS) that placed you in the autism range, either recently or within the past 5 years.
  • A doctor has rated your overall condition as moderately severe or above on a standard severity scale at the start of the study.
  • Your score on a standard behavior checklist measuring irritability and agitation is 18 or above at the screening visit.
  • Your resting heart rate is above 60 beats per minute and your resting blood pressure is above 100/60.
  • You have someone in your life (a study partner) who spends at least 5 hours per week with you, can reliably report on your behaviors and symptoms, and can help with safety monitoring and other tasks required during the study.
  • If you are someone who could become pregnant and are sexually active, you must agree to use two forms of effective contraception from screening through 30 days after your last dose of study medication.
  • You are able to swallow the study medication capsule whole.
  • English is your primary language, and your study partner can read, consent, and complete study forms in English.

Who may not be able to join:

  • You cannot give informed consent yourself and do not have a parent, guardian, or legally authorized representative who can consent on your behalf.
  • Your psychiatric medications or behavioral treatment program have changed within the past two months before joining the study (unless the change was due to a school, vocational, or daily schedule change).
  • You have asthma or any condition involving airway narrowing (bronchoconstriction) in the past 5 years.
  • You have a heart condition that would make taking high doses of propranolol unsafe, as determined by a heart specialist (confirm with trial site).
  • You have a seizure disorder that is not well controlled — meaning you have had a seizure in the past year or your seizure medication has changed in the past six months.
  • You have diabetes.
  • You have lactose intolerance that requires you to completely avoid all dairy products or take lactase supplements.
  • You have a history of kidney or liver problems.
  • You have a history of low blood sugar (hypoglycemia).
  • You are unable to have blood drawn when the study's safety doctor determines it is medically necessary.
  • You are currently experiencing, or have experienced in the past six months, a depressive episode.
  • You have had an allergic reaction or a bad reaction to propranolol or any other beta-blocker medication in the past.
  • You are currently taking certain medications, including (but not limited to): propafenone, quinidine, amiodarone, lidocaine, digoxin, calcium channel blockers, ACE inhibitors, clonidine, alpha blockers, reserpine, epinephrine, isoproterenol, dobutamine, indomethacin, MAO inhibitors, tricyclic antidepressants, certain anesthetic agents, warfarin, haloperidol, thyroxine, or alcohol (confirm full medication list with trial site).
  • You have any other medical condition or take any other medication that would make using propranolol unsafe (confirm with trial site).
  • The study investigator decides for any reason that the study is not right for you.
  • You have taken part in another clinical drug or device study within the past 3 months.
  • You are unable to have your blood pressure checked or have an ECG (heart tracing) done as part of safety monitoring.
  • You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jeremy Veenstra-VanderWeele, MD, New York State Psychiatric Institute

Phone: 914-997-5587

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jeremy Veenstra-vanderweele
Registry
ClinicalTrials.gov
Start date
30 January 2026
Est. completion
1 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of safety concerns and side effects associated with high-dose propranolol, including changes in blood pressure, pulse, and occurrence of dysrhythmias.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov